This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Rubius Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Rubius Therapeutics şirketinin toplam hissedar öz sermayesi $15.1M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $23.1M ve $7.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$14.87m
Eşitlik	US$15.13m
Toplam yükümlülükler	US$7.94m
Toplam varlıklar	US$23.07m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 5RT 'nin kısa vadeli varlıkları ( $20.2M ) kısa vadeli yükümlülüklerini ( $7.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: 5RT un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 5RT borçsuzdur.

Borcun Azaltılması: 5RT şirketinin 5 yıl önce borç/öz sermaye oranı 5.6% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 5RT şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: 5RT un, serbest nakit akışı her yıl % 23 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

This company listing is no longer active

Rubius Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

Recent updates

Less than half of directors are independent

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

High number of new and inexperienced directors

Rubius Therapeutics, Inc. Announces Leadership Changes

Rubius Therapeutics, Inc. Announces Resignation of David Epstein as a Member of the Board

Rubius Therapeutics Announces Strategic Update

Rubius Therapeutics, Inc. Announces Resignation of Natalie Holles as Member of the Board of Directors

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

Rubius Therapeutics, Inc. Appoints Susanne Schaffert to Its Board of Directors

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 2000 Growth Index

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Rubius Therapeutics, Inc. Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

Rubius Therapeutics, Inc., Annual General Meeting, May 12, 2022

Rubius Therapeutics, Inc. to Report Q4, 2021 Results on Feb 25, 2022

Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

Rubius Therapeutics to Highlight the Power of RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day

Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 3000E Value Index

Rubius Therapeutics, Inc. Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® in Ongoing Phase 1/2 Clinical Trial for Treatment of Advanced Solid Tumors

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications

Rubius Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

Rubius Therapeutics Announces Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240

New 90-day high: €12.50

Rubius Therapeutics, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: €8.10

Rubius Therapeutics, Inc. Provides an Operational Update

New 90-day high: €7.90

New 90-day high: €4.92

Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic Clinical Oncology Program, Rtx-240, at the Society for Immunotherapy of Cancer’s Annual Meeting

Rubius Therapeutics, Inc. Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240

Rubius Therapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low: €3.84

Rubius Therapeutics, Inc. Appoints Jose Carmona as Principal Financial Officer, Principal Accounting Officer and Treasurer Effective as of October 1, 2020

New 90-day low: €3.92

New 90-day low - €4.00

Rubius Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

New 90-day low - €4.92

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin